Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 4Urinary Bladder Neoplasms 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Head and Neck Neoplasms 2Acrocephalosyndactylia 2Small Cell Lung Carcinoma 1Sarcoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Cancer Metastatic 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Rogaratinib × Clear all
NCT03517956 2022-07-14

ROCOCO

Bayer

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡